J Thorac Cardiovasc Surg 2004;127:605
© 2004 The American Association for Thoracic Surgery
Letter to the editor
300 Elliot St, Newton, MA 02464, USA
|The first 20% of the full text of this article appears below.|
To the Editor:
Ott and colleagues,1 and the editorial staff of the Journal,deserve much credit for carrying out and publishing a study on the use of cyclooxygenase 2 inhibitors for postoperative pain after coronary artery bypass grafting. However, the study report is beset with serious deficiencies in the presentation of the study results, which should be noted to avoid similar deficiencies in what I hope will be future publications of studies on postoperative pain relief.
Ott and colleagues1 commendably sought to provide a risk-benefit assessment of the use of parecoxib and valdecoxib in the postcoronary artery bypass grafting setting by reporting on both the degree of pain relief and differences in adverse effects associated with the study drugs relative to the control group. The first issue is the choice of primary outcome measure: amount of reduction in morphine
J. Thorac. Cardiovasc. Surg. 2004 127: 606.
This article has been cited by other articles:
M. W. Khalil, A. Chaterjee, G. MacBryde, P. K. Sarkar, and R. R. D. Marks
Single dose parecoxib significantly improves ventilatory function in early extubation coronary artery bypass surgery: a prospective randomized double blind placebo controlled trial
Br. J. Anaesth., February 1, 2006; 96(2): 171 - 178.
[Abstract] [Full Text] [PDF]
|HOME||HELP||FEEDBACK||SUBSCRIPTIONS||ARCHIVE||SEARCH||TABLE OF CONTENTS|
|ANN THORAC SURG||ASIAN CARDIOVASC THORAC ANN||EUR J CARDIOTHORAC SURG|
|J THORAC CARDIOVASC SURG||ICVTS||ALL CTSNet JOURNALS|